Literature DB >> 2751746

Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration.

C L Malmendier1, J F Lontie, C Delcroix, D Y Dubois, T Magot, L De Roy.   

Abstract

Four hypertriglyceridemic patients, who had received an equilibrated high calorie diet and no lipid lowering drug for 1 month, were injected intravenously with 125I-apo C-II and 131I-apo C-III labeled homologous lipoproteins. Plasma and urine radioactivity, lipid and apolipoprotein levels were followed at regular intervals for 15 days. At the end of this first kinetic study the patients were advised to adhere for 1 month to a more restricted diet, limited in fat, and were given additionally 300 mg fenofibrate daily. After this treatment, a new kinetic study involving intravenous injection (similar to the first one) was performed. The protocols of both studies were identical. Treatment (diet plus drug) (1) reduced total cholesterol by 26 +/- 8%, triglycerides by 56 +/- 15%, apo C-II by 36 +/- 14%, and apo C-III by 48 +/- 10%; (2) modified the distribution of radioactivity between lipoproteins proportionally to the change in their mass ratio (decrease in VLDL and increase in HDL); (3) changed the kinetics of both apoproteins by rising the fractional removal rate, shortening residence time and decreasing the synthesis rate of both apolipoproteins C-II and C-III. The treatment was, however, unable to reduce the synthesis rate of apo C-III to normal, suggesting a major role of the apoprotein overproduction in the triggering of hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2751746     DOI: 10.1016/0021-9150(89)90075-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  19 in total

1.  Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.

Authors:  Silvia Bijland; Elsbet J Pieterman; Annemarie C E Maas; José W A van der Hoorn; Marjan J van Erk; Jan B van Klinken; Louis M Havekes; Ko Willems van Dijk; Hans M G Princen; Patrick C N Rensen
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

2.  Characterization of the adipose tissue atrophy induced by peroxisome proliferators in mice.

Authors:  Yi Xie; Qian Yang; B Dean Nelson; Joseph W DePierre
Journal:  Lipids       Date:  2002-02       Impact factor: 1.880

3.  A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Authors:  Sumeet A Khetarpal; Xuemei Zeng; John S Millar; Cecilia Vitali; Amritha Varshini Hanasoge Somasundara; Paolo Zanoni; James A Landro; Nicole Barucci; William J Zavadoski; Zhiyuan Sun; Hans de Haard; Ildikó V Toth; Gina M Peloso; Pradeep Natarajan; Marina Cuchel; Sissel Lund-Katz; Michael C Phillips; Alan R Tall; Sekar Kathiresan; Paul DaSilva-Jardine; Nathan A Yates; Daniel J Rader
Journal:  Nat Med       Date:  2017-08-21       Impact factor: 53.440

Review 4.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.

Authors:  J A Balfour; D McTavish; R C Heel
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

5.  An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms.

Authors:  M Dammerman; L A Sandkuijl; J L Halaas; W Chung; J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

6.  Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.

Authors:  Kazunori Nagashima; Carlos Lopez; Daniel Donovan; Colleen Ngai; Nelson Fontanez; André Bensadoun; Jamila Fruchart-Najib; Steve Holleran; Jeffrey S Cohn; Rajasekhar Ramakrishnan; Henry N Ginsberg
Journal:  J Clin Invest       Date:  2005-04-01       Impact factor: 14.808

Review 7.  The role of fibric acid derivatives in the secondary prevention of coronary heart disease.

Authors:  J Krakoff; B S Vela; E A Brinton
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

Review 8.  Targeting ApoC-III to Reduce Coronary Disease Risk.

Authors:  Sumeet A Khetarpal; Arman Qamar; John S Millar; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2016-09       Impact factor: 5.113

9.  Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

Authors:  Dick C Chan; Minh N Nguyen; Gerald F Watts; P Hugh R Barrett
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

10.  Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.

Authors:  N Vu-Dac; P Gervois; I P Torra; J C Fruchart; V Kosykh; T Kooistra; H M Princen; J Dallongeville; B Staels
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.